ClinicalTrials.gg
CompletedNCT00150449Updated Jul 14, 2006

Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.

A Phase 3 interventional study of Pregabalin in Anxiety Neuroses, sponsored by Pfizer. Completed at 138 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2006-07-14.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
511
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 231 studies in Anxiety Disorders with a site in United Kingdom — 36 open to participants now, 38 under way, none of them phase 3. Anxiety Disorders · United Kingdom.

Enrollment
14th of 183
511 · median 60
Started
2001
with 1 other
Phase 3
7 of 231
none open now
Registered
3rd of 231
by date

Among the 231 studies in Anxiety Disorders with a site in United Kingdom, this one is the 14th largest by enrollment of the 183 interventional ones that give a count, is one of 2 that started in 2001, is one of 7 in phase 3, and was the 3rd registered.

Anxiety Disorders

7,238 studies on the registry are indexed under Anxiety Disorders; 1,687 are open to participants now.

Browse Anxiety Disorders studies →

Open to participants now

36 of the 231 studies in Anxiety Disorders with a site in United Kingdom are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 948 Anxiety Disorders studies recruiting now, 423 (45%) set no upper age limit and 457 (48%) stop at 75 or younger; 234 take children under 18; 321 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 231 studies in Anxiety Disorders with a site in United Kingdom, or all of them as a file.
02

Study summary

Determine long-term safety and tolerability of pregabalin in patients with anxiety disorders.

03

Conditions studied

  • Anxiety Neuroses

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have completed the double-blind portion of the preceding trial
  • Completed any protocol specified withdrawal phase and follow-up visits.

Exclusion criteria

Exclusion Criteria:

  • Patient cannot participate if they experienced a serious adverse event or a nonserious, but medically significant adverse event during the preceding efficacy study that was judged to be related to the study medication.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
511 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Safety Tolerability

07

Study locations

138 sites
  • Pfizer Investigational Site
    A-1040 Wien, Austria
  • Pfizer Investigational Site
    Wein, A-1020, Austria
  • Pfizer Investigational Site
    Wien, A-1050, Austria
  • Pfizer Investigational Site
    Brussels, 1020, Belgium
  • Pfizer Investigational Site
    De Pinte, 9840, Belgium
  • Pfizer Investigational Site
    Gent, 9000, Belgium
  • Pfizer Investigational Site
    Kortrijk, 8500, Belgium
  • Pfizer Investigational Site
    Lede, 9340, Belgium
  • Pfizer Investigational Site
    Liege, B-4000, Belgium
  • Pfizer Investigational Site
    Sint-Denijs-Westrem, 9051, Belgium
  • Pfizer Investigational Site
    Tielt, 8700, Belgium
  • Pfizer Investigational Site
    Tournai, 7500, Belgium
  • Pfizer Investigational Site
    Tallinn, 10614, Estonia
  • Pfizer Investigational Site
    Tartu, 50417, Estonia
  • Pfizer Investigational Site
    Reims, Cedex 51092, France
  • Pfizer Investigational Site
    Denguin, 64230, France
  • Pfizer Investigational Site
    Elancourt, 78990, France
  • Pfizer Investigational Site
    Metz, F-57000, France
  • Pfizer Investigational Site
    Montesson, 78360, France
  • Pfizer Investigational Site
    Montigny les Metz, 57950, France
  • Pfizer Investigational Site
    Saint Etienne du Gres, 13103, France
  • Pfizer Investigational Site
    Wasquehal, 59290, France
  • Pfizer Investigational Site
    Bad-Deurrheim, 78073, Germany
  • Pfizer Investigational Site
    Bremerhaven, 27568, Germany
  • Pfizer Investigational Site
    Gottingen, D-37073, Germany
  • Pfizer Investigational Site
    Gottingen, D-37085, Germany
  • Pfizer Investigational Site
    Hamburg, D-22767, Germany
  • Pfizer Investigational Site
    Kothen, D-06366, Germany
  • Pfizer Investigational Site
    Lauf, 77886, Germany
  • Pfizer Investigational Site
    Oldenburg, 26121, Germany
  • Pfizer Investigational Site
    Osnabrueck, 49078, Germany
  • Pfizer Investigational Site
    Siegen, 57072, Germany
  • Pfizer Investigational Site
    Spaichingen, 78549, Germany
  • Pfizer Investigational Site
    Ness Ziona, 70450, Israel
  • Pfizer Investigational Site
    Bassano del Grappa (Vicenza), 36061, Italy
  • Pfizer Investigational Site
    Bologna, 40123, Italy
  • Pfizer Investigational Site
    Milano, Italy
  • Pfizer Investigational Site
    Roma, 00122, Italy
  • Pfizer Investigational Site
    Riga, Latvia
  • Pfizer Investigational Site
    Ambacht, 3341 CS HI, Netherlands
  • Pfizer Investigational Site
    BV Losser, 7581, Netherlands
  • Pfizer Investigational Site
    GC Nijmegen, 6525, Netherlands
  • Pfizer Investigational Site
    Hoogvliet, 3192 JN, Netherlands
  • Pfizer Investigational Site
    Huizen, 1271 BB, Netherlands
  • Pfizer Investigational Site
    Losser, 7581 BV, Netherlands
  • Pfizer Investigational Site
    RC Dordrecht, 3317, Netherlands
  • Pfizer Investigational Site
    Zwigndrecht, 3333 EP, Netherlands
  • Pfizer Investigational Site
    Zwijndreacht, 3334 XA, Netherlands
  • Pfizer Investigational Site
    Zwijndrecht, 3331 AE, Netherlands
  • Pfizer Investigational Site
    Zwijndrecht, 3332 AJ, Netherlands
  • Pfizer Investigational Site
    Zwijndrecht, 3335 EJ, Netherlands
  • Pfizer Investigational Site
    Bialystok, 15-420, Poland
  • Pfizer Investigational Site
    Bydgoszcz, 85-096, Poland
  • Pfizer Investigational Site
    Katowice, 40-635, Poland
  • Pfizer Investigational Site
    Olsztyn, 10-511, Poland
  • Pfizer Investigational Site
    Torun, 87-100, Poland
  • Pfizer Investigational Site
    Tuszyn, 95-080, Poland
  • Pfizer Investigational Site
    Warszawa, 02-957, Poland
  • Pfizer Investigational Site
    Wroclaw, 50-229, Poland
  • Pfizer Investigational Site
    Zabrze, 41-800, Poland
  • Pfizer Investigational Site
    Goodwood, Cape Town 7460, South Africa
  • Pfizer Investigational Site
    Paarl, Cape Town 7646, South Africa
  • Pfizer Investigational Site
    Kempton Park, Johannesburg 1619, South Africa
  • Pfizer Investigational Site
    Rosebank, Johannesburg 2196, South Africa
  • Pfizer Investigational Site
    Hatfield, Pretoria 0083, South Africa
  • Pfizer Investigational Site
    Bellville, 7530, South Africa
  • Pfizer Investigational Site
    Bloemfontein, 9301, South Africa
  • Pfizer Investigational Site
    Bloemfontein, 9330, South Africa
  • Pfizer Investigational Site
    East London, 5201, South Africa
  • Pfizer Investigational Site
    George, 6529, South Africa
  • Pfizer Investigational Site
    Hurlingham, Johannesburg, 2070, South Africa
  • Pfizer Investigational Site
    Pietersburg, 0699, South Africa
  • Pfizer Investigational Site
    Pinetown Natal, 3610, South Africa
  • Pfizer Investigational Site
    Pretoria, 0002, South Africa
  • Pfizer Investigational Site
    Pretoria, 0181, South Africa
  • Pfizer Investigational Site
    Sandton, 2196, South Africa
  • Pfizer Investigational Site
    Somerset West, 7130, South Africa
  • Pfizer Investigational Site
    Westville, 3630, South Africa
  • Pfizer Investigational Site
    Oviedo, Asturias 33011, Spain
  • Pfizer Investigational Site
    Granollers, Barcelona 08400, Spain
  • Pfizer Investigational Site
    Barcelona, 08036, Spain
  • Pfizer Investigational Site
    Barcelona, 08100, Spain
  • Pfizer Investigational Site
    Madrid, 28006, Spain
  • Pfizer Investigational Site
    Madrid, 28009, Spain
  • Pfizer Investigational Site
    Madrid, 28037, Spain
  • Pfizer Investigational Site
    Madrid, 28041, Spain
  • Pfizer Investigational Site
    Pamplona, 31014, Spain
  • Pfizer Investigational Site
    Sevilla, 41700, Spain
  • Pfizer Investigational Site
    Zaragoza, 50007, Spain
  • Pfizer Investigational Site
    Kharkov, 61068, Ukraine
  • Pfizer Investigational Site
    Lviv, 79021, Ukraine
  • Pfizer Investigational Site
    Odessa, 65006, Ukraine
  • Pfizer Investigational Site
    Maidenhead, Berkshire SL6 2LH, United Kingdom
  • Pfizer Investigational Site
    Slough, Berks SL2 1HD, United Kingdom
  • Pfizer Investigational Site
    Falmouth, Cornwall TR11 2LH, United Kingdom
  • Pfizer Investigational Site
    Fowey, Cornwall PL23 1DT, United Kingdom
  • Pfizer Investigational Site
    Penzance, Cornwall TR18 4JH, United Kingdom
  • Pfizer Investigational Site
    Saltash, Cornwall PL12 6DL, United Kingdom
  • Pfizer Investigational Site
    St. Austell, Cornwall PL26 7RL, United Kingdom
  • Pfizer Investigational Site
    Downpatrick, County Down BT30 6HY, United Kingdom

Showing the first 100 of 138 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Montgomery S, Emir B, Haswell H, Prieto R. Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability. Curr Med Res Opin. 2013 Oct;29(10):1223-30. doi: 10.1185/03007995.2013.820694. Epub 2013 Aug 19. PubMed 23808960 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2001 and a completion of Mar 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2005
First posted
Sep 8, 2005
Start
Jan 2001
Completion
Mar 2006
Last update
Jul 14, 2006
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Jul 14, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00150449
Lead sponsor
Pfizer
First posted
Sep 8, 2005
Start date
Jan 2001
Completion
Mar 2006
Last update
Jul 14, 2006

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion